KCM
ABMD

KRS Capital Management’s Abiomed Inc ABMD Stock Holding History

KRS Capital Management’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-75
Closed -$26K – 393
2021
Q4 		$26K Buy
+75
New +$25.3K 0.02% 272

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

KRS Capital Management's ABMD Position: Q1 2022 in Review

KRS Capital Management sold out of Abiomed Inc (ABMD) in Q1 2022, closing a stake of 75 shares — an estimated $26K sold.

KRS Capital Management first reported a position in ABMD in Q4 2021 and held it in 1 quarter. The position peaked at $26K in Q4 2021. 500 funds tracked by Wall St. Rank hold ABMD as of Q1 2022.

  • KRS Capital Management reported no remaining Abiomed Inc position as of Q1 2022 after selling out during the quarter.
  • KRS Capital Management sold 75 Abiomed Inc shares in Q1 2022, an estimated $26K.
  • KRS Capital Management first reported a position in Abiomed Inc in Q4 2021 and held it in 1 quarter.
  • KRS Capital Management's Abiomed Inc position peaked at $26K in Q4 2021.
  • 500 funds tracked by Wall St. Rank held Abiomed Inc as of Q1 2022.

Based on KRS Capital Management's 13F filing for Q1 2022, filed 27 Apr 2022.